The Australian Stock Exchange has created a market that attracts not only local biotechnology companies, but also gives opportunities to foreign companies that would be unable to attract capital in their own markets. Helen Schuller reports.

Auckland-based cell therapy company Living Cell Technologies (ASX:LCT) will hold a general meeting next week to formally seal a deal under which it has acquired technology and IP worth US$90 million from with US cell-therapy company Theracyte.

The Lorne Proteomics Symposium is geared towards assessing practical solutions for the technology.

The Lorne Conference on Protein Structure and Function is celebrating its 30th anniversary this year. Graeme O'Neill discovers why there's plenty to celebrate.

At the suggestion of eminent UK neuroscience researcher Baroness Susan Greenfield, the South Australian Government is establishing an Australian Science Media Centre (AusSMC) in Adelaide to serve as a national portal for the media to obtain expert advice on science subjects.

Cell therapy company Living Cell Technologies (LCT) is planning to list on the ASX in the next few months, after completing a rights issue which will provide it with AUD$4.8 million cash and the ability to upgrade from its current listing on the Newcastle Stock Exchange (NSX:LCT).

Some Australian listed biotechs are trapped in a death spiral. Shareholders are reluctant to top up their original investments, while cash burn rates tip them ever closer to the edge of insolvency. But there are bright spots, writes Pete Young